Clinical trials: Active Population
Scalp Psoriasis
Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis
The study will be conducted to evaluate the efficacy and safety of a topical dimeticone formulation (Loion®) compared to 10% salicylic acid in octyl-dodecanol with 15% Macrogol-4-laurylether for the removal of scaling in patients…
- Trial name
- NCT01914627
- Testing
- Dimethicone, Salicylic Acid
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- G. Pohl-Boskamp GmbH & Co. KG
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment…
- Trial name
- NCT02616562
- Testing
- somapacitan, Norditropin® FlexPro® pen
- Where
- 89 sites in United States, Austria and 12 more
- Volunteers
- 76 people
- Sponsor
- Novo Nordisk A/S
Crohn's Disease
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
The primary objectives of the study are: To evaluate the safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD） To evaluate the clinical efficacy of MT-1303 in subjects with moderate to…
- Trial name
- NCT02378688
- Testing
- MT-1303
- Where
- 11 sites in Czechia, France and 9 more
- Volunteers
- 78 people
- Sponsor
- Tanabe Pharma Corporation
Malnutrition
Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age
Demonstrate the safety and efficacy of Kabiven compared to standard parenteral nutrition (PN) administered via central vein in pediatric patients (2 to 16 years of age) requiring PN to meet nutritional needs.
- Trial name
- NCT03481894
- Testing
- Kabiven®, Compounded standard parenteral nutrition
- Where
- 2 sites in United States
- Sponsor
- Fresenius Kabi
Psoriatic Arthritis
Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis
This is a multicenter, double-blind, randomized, parallel-group study to compare the efficacy,pharmacodynamics (PD), pharmacokinetics (PK), safety, and immunogenicity of BAT2506 versus Simponi® in participants with active PsA.
- Trial name
- NCT05046431
- Testing
- BAT2506, EU Simponi
- Where
- China
- Volunteers
- 704 people
- Sponsor
- Bio-Thera Solutions
Rheumatoid Arthritis
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.
- Trial name
- NCT04413617
- Testing
- PF-06650833, PF-06651600, Tofacitinib
- Where
- 144 sites in Bulgaria, Canada and 8 more
- Volunteers
- 460 people
- Sponsor
- Pfizer
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Total Knee Replacement, Postoperative Pain
Safety and Activity of F14 for Management of Pain Following Total Knee Replacement
The safety and activity of a single, 3.5 mL dose of F14 (celecoxib) concurrent with standard of care analgesia administered following total knee replacement will be compared to standard of care analgesia alone.
- Trial name
- NCT03541655
- Testing
- Bupivacaine HCl, F14 (celecoxib)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Arthritis Innovation Corporation
Peripheral Arterial Disease
Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, has been widely used as an anti-platelet agent for the treatment of PAD.
- Trial name
- DAVICI (NCT02393612)
- Testing
- DP-R202, Anplag tab
- Volunteers
- 151 people
- Sponsor
- Alvogen Korea
Ulcerative Colitis
Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis
This is a Phase 2, multi center, randomized, placebo controlled parallel group study to evaluate the clinical efficacy and safety of LC51 0255 in subjects with moderately to severely active ulcerative colitis
- Trial name
- NCT04096573
- Testing
- LC51-0255
- Sponsor
- LG Chem
Moderate Clostridium Difficile Infection
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
This study will assess the safety and efficacy of multiple daily dosing of oral LFF571 in patients who have moderate Clostridium difficile infections.
- Trial name
- NCT01232595
- Testing
- LFF571, Vancomycin (POC)
- Where
- 18 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with…
- Trial name
- ZENITH-CKD (NCT04724837)
- Testing
- Zibotentan, Dapagliflozin
- Where
- 164 sites in United States, Argentina and 17 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
- Trial name
- NCT02447302
- Testing
- Etrasimod
- Where
- 134 sites in United States, Australia and 19 more
- Volunteers
- 156 people
- Sponsor
- Arena Pharmaceuticals
Type 2 Diabetes Mellitus
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or…
- Trial name
- NCT01699737
- Testing
- JTT-851, Glimepiride
- Where
- 79 sites in United States
- Volunteers
- 325 people
- Sponsor
- Shionogi Inc.
Osteoarthitis, Chronic Pain
Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis
The purpose of this study was to examine a low and high dose of tapentadol extended release tablet taken orally twice a day to reduce pain in subjects suffering from chronic moderate to severe pain due to osteoarthritis of the…
- Conditions
- Osteoarthitis, Chronic Pain, Knee Pain
- Trial name
- NCT00745069
- Testing
- tapentadol HCl
- Volunteers
- 670 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
- Trial name
- NCT06063473
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
- Where
- United States
- Volunteers
- 762 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Primary Sjögren's Syndrome
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).
- Trial name
- NCT06979531
- Testing
- IMVT-1402
- Where
- 96 sites in United States, Argentina and 11 more
- Volunteers
- 180 people
- Sponsor
- Immunovant Sciences GmbH
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment.
- Trial name
- NCT07766499
- Testing
- THB335 Lower Dose, THB335 Higher Dose
- Where
- 15 sites in United States
- Volunteers
- 81 people
- Sponsor
- Calixis Inc.
COPD
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.
- Trial name
- KRONOS (NCT02497001)
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg
- Where
- 190 sites in United States, Canada and 2 more
- Volunteers
- 1,902 people
- Sponsor
- Pearl Therapeutics, Inc.
Dry Eye Disease
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
- Trial name
- NCT07128628
- Testing
- Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane
- Where
- 32 sites in United States
- Volunteers
- 443 people
- Sponsor
- Bausch & Lomb Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.